Comparison · NCT02713529-deaths
AMG 820 1100 MG vs AMG 820 1400 MG: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AMG 820 1100 MG vs AMG 820 1400 MG: deaths from any cause. Trial comparisons, record NCT02713529-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02713529-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.122 | 0.0715 | 0.202 | wilson | |
| Risk in group 2 | 0.0556 | 0.00988 | 0.258 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0669 | -0.141 | 0.159 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.2 | 0.305 | 15.9 | log | |
| Odds ratio, group 1 over group 2 | 2.37 | 0.289 | 19.5 | log | |
| Number needed to harm, for one more death from any cause on AMG 820 1100 MG than on AMG 820 1400 MG | 14.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AMG 820 1100 MG | Includes participants from all treatment arms that were administered AMG 820 1100 mg. | 12 | 98 | EG000 |
| Group 2 | AMG 820 1400 MG | Includes participants from all treatment arms that were administered AMG 820 1400 mg. | 1 | 18 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- The TEAE timeframe was Day 1 up to 207 days for Part 1 and Day 1 up to 572 days for Part 2. The median time frame is 122 days.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
- NCT number
- NCT02713529
- Phases
- PHASE1, PHASE2
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer
- Interventions
- AMG820 and pembrolizumab
- Lead sponsor
- AmMax Bio, Inc.
- Results first posted
- 2020-06-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02713529?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02713529-deaths